Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives,EJNMMI Radiopharmacy and Chemistry

当前位置： X-MOL 学术 › EJNMMI Radiopharm. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives
EJNMMI Radiopharmacy and Chemistry Pub Date : 2024-02-06 , DOI: 10.1186/s41181-024-00239-1
Eline L. Hooijman , Valery Radchenko , Sui Wai Ling , Mark Konijnenberg , Tessa Brabander , Stijn L. W. Koolen , Erik de Blois

In the past years, there has been a notable increase in interest regarding targeted alpha therapy using Ac-225, driven by the observed promising clinical anti-tumor effects. As the production and technology has advanced, the availability of Ac-225 is expected to increase in the near future, making the treatment available to patients worldwide. Ac-225 can be labelled to different biological vectors, whereby the success of developing a radiopharmaceutical depends heavily on the labelling conditions, purity of the radionuclide source, chelator, and type of quenchers used to avoid radiolysis. Multiple (methodological) challenges need to be overcome when working with Ac-225; as alpha-emission detection is time consuming and highly geometry dependent, a gamma co-emission is used, but has to be in equilibrium with the mother-nuclide. Because of the high impact of alpha emitters in vivo it is highly recommended to cross-calibrate the Ac-225 measurements for used quality control (QC) techniques (radio-TLC, HPLC, HP-Ge detector, and gamma counter). More strict health physics regulations apply, as Ac-225 has a high toxicity, thereby limiting practical handling and quantities used for QC analysis. This overview focuses specifically on the practical and methodological challenges when working with Ac-225 labelled radiopharmaceuticals, and underlines the required infrastructure and (detection) methods for the (pre-)clinical application.

更新日期：2024-02-07

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文

全部期刊列表>>